Evidence map›Paper›PMID 33600377›Full record

ArticleJCI insight2021

15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration.

Julianne Np Smith, Dawn M Dawson, Kelsey F Christo, Alvin P Jogasuria, Mark J Cameron, Monika I Antczak, Joseph M Ready, Stanton L Gerson, Sanford D Markowitz, Amar B Desai

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Molecular evolution of animal aging.The EMBO journal · 2026
    Review
  2. Review
  3. Article
  4. The spleen in ischaemic heart disease.Nature reviews. Cardiology · 2025
    Review
  5. Prostaglandin EEXCLI journal · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Julianne Np SmithDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Dawn M DawsonDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Kelsey F ChristoDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Alvin P JogasuriaDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Mark J CameronDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Monika I AntczakDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Joseph M ReadyDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Stanton L GersonDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Sanford D MarkowitzDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Amar B DesaiDepartment of Medicine and Case Comprehensive Cancer Center Case Western Reserve University, Cleveland, Ohio, USA.
Case Western Reserve University · USThe University of Texas Southwestern Medical Center · USUniversity Hospitals Seidman Cancer Center · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and TreatmentR35CA197442 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2017 to 2023
$6.6M
Translational Research in Regenerative MedicineT32EB005583 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI LEE, KIBUM, PAREKKADAN, BIJU · 2006 to 2022
$4.7M
Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell TransplantationR01CA216863 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERSON, STANTON L., MARKOWITZ, SANFORD D. · 2017 to 2019
$1.9M
Towards Improving Bone Marrow Transplantation via Inhibition of 15-PGDHR00HL135740 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI DESAI, AMAR · 2020 to 2022
$747k
Towards Improving Bone Marrow Transplantation via Inhibition of 15-PGDHK99HL135740 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI DESAI, AMAR · 2017 to 2018
$260k
NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA216863NCI NIH HHS R35 CA197442NHLBI NIH HHS K99 HL135740NHLBI NIH HHS R00 HL135740NIBIB NIH HHS T32 EB005583
6 · The paper itself

Abstract

The splenic microenvironment regulates hematopoietic stem and progenitor cell (HSPC) function, particularly during demand-adapted hematopoiesis; however, practical strategies to enhance splenic support of transplanted HSPCs have proved elusive. We have previously demonstrated that inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH), using the small molecule (+)SW033291 (PGDHi), increases BM prostaglandin E2 (PGE2) levels, expands HSPC numbers, and accelerates hematologic reconstitution after BM transplantation (BMT) in mice. Here we demonstrate that the splenic microenvironment, specifically 15-PGDH high-expressing macrophages, megakaryocytes (MKs), and mast cells (MCs), regulates steady-state hematopoiesis and potentiates recovery after BMT. Notably, PGDHi-induced neutrophil, platelet, and HSPC recovery were highly attenuated in splenectomized mice. PGDHi induced nonpathologic splenic extramedullary hematopoiesis at steady state, and pretransplant PGDHi enhanced the homing of transplanted cells to the spleen. 15-PGDH enzymatic activity localized specifically to macrophages, MK lineage cells, and MCs, identifying these cell types as likely coordinating the impact of PGDHi on splenic HSPCs. These findings suggest that 15-PGDH expression marks HSC niche cell types that regulate hematopoietic regeneration. Therefore, PGDHi provides a well-tolerated strategy to therapeutically target multiple HSC niches, promote hematopoietic regeneration, and improve clinical outcomes of BMT.

Indexed as

RegenerationAnimalsBone Marrow CellsEnzyme InhibitorsFemaleGene Expression ProfilingHematopoiesis, ExtramedullaryHydroxyprostaglandin DehydrogenasesMiceMice, Inbred C57BLSpleen15-hydroxyprostaglandin dehydrogenaseEnzyme InhibitorsHydroxyprostaglandin DehydrogenasesEicosanoidsHematologyHematopoietic stem cells

Identifiers

PMID33600377
PMCPMC8026178
OpenAlexW3131308878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.